NASDAQ:ACHV

Achieve Life Sciences (ACHV) Stock Forecast, Price & News

$4.40

-0.01 (-0.23%)

(As of 09/21/2023 ET)

Compare

Today's Range: $4.35
▼
$4.47
50-Day Range: $4.40
▼
$5.68
52-Week Range: $2.00
▼
$10.30

Volume: 37,157 shs
Average Volume: 46,763 shs
Market Capitalization: $92.88 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.67

Achieve Life Sciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 324.2% Upside
$18.67 Price Target
Short Interest: Bearish
3.41% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.33
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.62) to ($1.61) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

746th out of 965 stocks

Diagnostic Substances Industry

10th out of 13 stocks

3.5

Analyst's Opinion

Consensus Rating
Achieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.67, Achieve Life Sciences has a forecasted upside of 324.2% from its current price of $4.40.
Amount of Analyst Coverage
Achieve Life Sciences has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.41% of the outstanding shares of Achieve Life Sciences have been sold short.
Short Interest Ratio / Days to Cover
Achieve Life Sciences has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Achieve Life Sciences has recently decreased by 1.25%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Achieve Life Sciences does not currently pay a dividend.
Dividend Growth
Achieve Life Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACHV.

1.8

News and Social Media Coverage

News Sentiment
Achieve Life Sciences has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Achieve Life Sciences this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Achieve Life Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Achieve Life Sciences is held by insiders.
Percentage Held by Institutions
43.65% of the stock of Achieve Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Achieve Life Sciences are expected to grow in the coming year, from ($1.62) to ($1.61) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Achieve Life Sciences is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Achieve Life Sciences is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Achieve Life Sciences has a P/B Ratio of 9.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Achieve Life Sciences (NASDAQ:ACHV) Stock

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.

ACHV Price History

30 days | 90 days | 365 days | Advanced Chart

ACHV Stock News Headlines

September 22, 2023 | nj.com

College Achieve Central defeats Delaware Valley - Boys soccer recap

September 20, 2023 | villagegreennj.com

The Achieve Foundation Newstead 5K is Saturday, September 30

September 22, 2023 | The Oxford Club (Ad)

Better Than Oil Stocks?

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

September 19, 2023 | usnews.com

Xi Says China, US 'Should and Must' Achieve Peaceful Co-Existence

September 15, 2023 | nj.com

Summit shuts out College Achieve Central - Boys soccer recap

September 1, 2023 | msn.com

Exit Realty Achieve: Making Realty A Supportive, Collaborative Business

August 16, 2023 | finance.yahoo.com

ACHV: 2Q:23 Results

August 16, 2023 | finance.yahoo.com

Q2 2023 Achieve Life Sciences Inc Earnings Call

September 22, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

August 15, 2023 | finance.yahoo.com

Individual investors account for 59% of Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) ownership, while institutions account for 40%

August 14, 2023 | finance.yahoo.com

Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update

August 4, 2023 | markets.businessinsider.com

Achieve announces close of $214 million, AAA-rated personal loan securitization

August 1, 2023 | finance.yahoo.com

Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast

July 18, 2023 | finance.yahoo.com

Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting

July 15, 2023 | finance.yahoo.com

ACHV - Achieve Life Sciences, Inc.

July 12, 2023 | usnews.com

LG Elec Says It Aims to Achieve $77 Billion in Sales by 2030

July 11, 2023 | finance.yahoo.com

Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)

June 6, 2023 | finance.yahoo.com

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

June 1, 2023 | msn.com

Lake Street Maintains Achieve Life Sciences (ACHV) Buy Recommendation

May 31, 2023 | bizjournals.com

Achieve Life Sciences raises $16.5M in pursuit of anti-smoking drug

May 25, 2023 | msn.com

Achieve Life Sciences stock down on pricing $16.5M stock offering

May 25, 2023 | finance.yahoo.com

ACHV: ORCA-3 Topline

May 25, 2023 | finance.yahoo.com

Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering

May 24, 2023 | finance.yahoo.com

Achieve Life Sciences, Inc.'s (NASDAQ:ACHV) Shift From Loss To Profit

May 23, 2023 | markets.businessinsider.com

Ladenburg Thalmann & Co. Sticks to Their Buy Rating for Achieve Life Sciences (ACHV)

May 23, 2023 | finance.yahoo.com

Can't Kick the Bud? Achieve's Cytisinicline Proves Promising in Phase 3 Smoking Cessation Trial

May 23, 2023 | finance.yahoo.com

Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial

See More Headlines

Receive ACHV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

ACHV Company Calendar

Last Earnings: 8/14/2023
Today: 9/21/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:ACHV
CUSIP: 68230A10
CIK: 949858
Web: achievelifesciences.com
Phone: (604) 210-2217
Fax: 425-686-1600
Employees: 20
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.67
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $17.00
Forecasted Upside/Downside: +324.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -852.58%
Return on Assets: -160.68%

Debt

Debt-to-Equity Ratio: 1.63
Current Ratio: 7.65
Quick Ratio: 7.65

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.46 per share
Price / Book: 9.57

Miscellaneous

Outstanding Shares: 21,106,000
Free Float: 20,684,000
Market Cap: $92.87 million
Optionable: Not Optionable
Beta: 1.52

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Richard A. B. Stewart (Age 64)
Exec. Chairman
Comp: $575k

Mr. John A. Bencich M.B.A. (Age 46)
CEO & Director
Comp: $733.12k

Dr. Cindy Jacobs M.D. (Age 65)
Ph.D., Pres, Chief Medical Officer & Director
Comp: $614.25k

Mr. Jerry Wan (Age 41)
Principal Accounting Officer

Dr. Anthony Clarke (Age 67)
Chief Scientific Officer

Ms. Jaime Xinos
Exec. VP of Commercial

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACHV Stock - Frequently Asked Questions

Should I buy or sell Achieve Life Sciences stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACHV shares.
View ACHV analyst ratings or view top-rated stocks.
What is Achieve Life Sciences' stock price forecast for 2023?: 2 equities research analysts have issued twelve-month price objectives for Achieve Life Sciences' shares. Their ACHV share price forecasts range from $17.00 to $20.00. On average, they expect the company's share price to reach $18.67 in the next twelve months. This suggests a possible upside of 324.2% from the stock's current price.
View analysts price targets for ACHV or view top-rated stocks among Wall Street analysts.
How have ACHV shares performed in 2023?: Achieve Life Sciences' stock was trading at $2.45 at the beginning of the year. Since then, ACHV shares have increased by 79.6% and is now trading at $4.40.
View the best growth stocks for 2023 here.
When is Achieve Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ACHV earnings forecast.
How were Achieve Life Sciences' earnings last quarter?: Achieve Life Sciences, Inc. (NASDAQ:ACHV) announced its earnings results on Monday, August, 14th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by $0.02.
When did Achieve Life Sciences' stock split?: Achieve Life Sciences's stock reverse split on the morning of Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Achieve Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).
What is Achieve Life Sciences' stock symbol?: Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."
Who are Achieve Life Sciences' major shareholders?: Achieve Life Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Shay Capital LLC (4.30%), AWM Investment Company Inc. (1.51%), B. Riley Wealth Advisors Inc. (1.20%), Geode Capital Management LLC (0.90%), LPL Financial LLC (0.82%) and Raymond James & Associates (0.76%).
View institutional ownership trends.
How do I buy shares of Achieve Life Sciences?: Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Achieve Life Sciences' stock price today?: One share of ACHV stock can currently be purchased for approximately $4.40.
How much money does Achieve Life Sciences make?: Achieve Life Sciences (NASDAQ:ACHV) has a market capitalization of $92.87 million. The biopharmaceutical company earns $-42,350,000.00 in net income (profit) each year or ($3.11) on an earnings per share basis.
How can I contact Achieve Life Sciences?: Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The official website for the company is achievelifesciences.com. The biopharmaceutical company can be reached via phone at (604) 210-2217, via email at jwong@bplifescience.com, or via fax at 425-686-1600.

This page (NASDAQ:ACHV) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial